<i>Genes, Cells and Brains</i> by Hilary Rose and Steven Rose - Review
By Steven Poole,
The Guardian (UK)
| 12. 19. 2012
We have outsourced the job of interpreting ourselves to the modern life sciences. The decoding of the human genome will tell us who we really are, pledged the gene-merchants. Brain scans will tell us who we really are, swore the neuro-hustlers. And what did we get? We got suckered. It turns out that humans have roughly as many protein-encoding genes as a fruit fly, and that
fMRI scanning is still such an inexact art that a team of satirical neuroscientists have demonstrated significant "brain activity" in a dead salmon.
This fascinating, lucid and angry book by the sociologist Hilary Rose and the neurobiologist Steven Rose (they are married) boasts abundant targets and a lethally impressive hit ratio. They decry the entrepreneurialisation of science – "wealth creation is now unabashedly formalised as the chief objective of science and technology policy" – not least because it actually impedes science. ("PhD students can work for months on a project only to find that they cannot continue as they have run into a patent.") They lambast the "armchair" theorising of evolutionary psychology, with its...
Related Articles
By Emily Baumgaertner Nunn, The New York Times | 09.08.2026
It is one of biology’s most ingenious rhythms: Every baby is born young. No matter how much wear and tear their parents’ DNA accumulated over their lifetimes, reproduction erases the molecular scars, handing a clean slate to the next generation...
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Jessica Hamzelou, MIT Technology Review | 07.23.2026
When it comes to organ donation, time is everything. As soon as an organ has been carefully removed from a donor’s body, it starts to deteriorate. Surgeons have a matter of hours to get it into a recipient. Leave...